Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000648137 | SCV000769951 | likely benign | Immunodeficiency, common variable, 2 | 2024-11-29 | criteria provided, single submitter | clinical testing | |
St. |
RCV000648137 | SCV005402344 | uncertain significance | Immunodeficiency, common variable, 2 | 2024-03-06 | criteria provided, single submitter | clinical testing | The TNFRSF13B c.828C>G (p.Asp276Glu) missense change has a maximum subpopulation frequency of 0.08% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. To our knowledge, this variant has not been reported in individuals with TNFRSFR13B-related diseases. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. |
Ambry Genetics | RCV005286156 | SCV005951206 | uncertain significance | Inborn genetic diseases | 2025-01-09 | criteria provided, single submitter | clinical testing | The c.828C>G (p.D276E) alteration is located in exon 5 (coding exon 5) of the TNFRSF13B gene. This alteration results from a C to G substitution at nucleotide position 828, causing the aspartic acid (D) at amino acid position 276 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |